Deal>

 

Hosted by              LSX with strap-3

DEAL OF THE YEAR (>£500M)


This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

Qualifying criteria
 
- Deal size must be equal to or greater than £500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH pharma, commercial leaders or big tech
- Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
- A license, partnership or alliance between companies NOT M&A
- Deal / milestone to have completed in the period between 1 September 2018 and 1 September 2019

Judges will be paying particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
- Post-deal performance
 
 
2019 WINNER
 
 
 
 
 
 
 
(L-R) Ellie Taylor, Emcee, Onno van de Stolpe, CEO, Galapagos, Maria Nichol, VP, Intellectual Property, Galapagos, Sofie van Gijsel, Galapagos and Josh Dance, SVP, LSX Leaders.
 
 
 
2019 HIGHLY COMMENDED
 
 
 
 
 

ALL 2019 FINALISTS

 

Bioarctic and Abbvie

BIOARCTIC AND ABBVIE

Crescendo Biologics and Takeda

CRESCENDO BIOLOGICS AND TAKEDA

Enterome and Takeda

ENTEROME AND TAKEDA

Galápagos and Gilead

GALÁPAGOS AND GILEAD

Immatics Biotechnologies and Celgene

IMMATICS BIOTECHNOLOGIES AND CELGENE

Silence Therapeutics and Mallinckrodt Pharmaceuticals

SILENCE THERAPEUTICS AND MALLINCKRODT

BUY TICKETS AND TABLES